Disease severity after whole parasite immunization. To determine disease severity after challenge, A/J mice were immunized with decreasing doses i.e., 10^8 , 10^3 , 10^2 or 0 (adjuvant alone) of (AS) parasitized red blood cells (pRBC) in CpG-ODN or control-ODN. Two weeks after immunization, mice were challenged i.v. with 10^5 homologous (AS) pRBC and disease severity monitored using clinical scores. Scores assessed five parameters including: weight loss (0-2), posture (0-2), activity (0-2), fur texture (0-2) and percent parasitemia (0-2) for a maximal score of 10. Data for individual mice are shown. Results are representative of three independent experiments performed.


Secretion of cytokines after CpG stimulation. (A) To determine the cell types responsible for the rapid cytokine secretion following by immunization, spleen cells from A/J mice immunized with 10³ (AS) pRBC in CpG-ODN (grey histograms) or control-ODN (clear histograms) were harvested 48 hours after immunization and stained directly *ex vivo*. T-cells (CD4⁺), NK cells (DX5⁺), macrophages (F4/80⁺), pDC (CD11c^{dim}B220⁺), cDC (CD11c⁺B220⁻) and B-cells (CD19⁺) were analyzed for secretion of IFN-γ, TNF-α, IL-12 and IL-10 by intracellular staining. Values indicate mean fluorescence intensity (MFI) on gated populations. (B) The profile of cytokine secretion induced was confirmed *in vitro* by culturing spleen cells from naïve A/J mice with 10³ (AS) pRBC parasites in decreasing doses of CpG or control-ODN (10, 1.0, 0.1 or 0 mM). Two days later, supernatants were collected and levels of IFN-γ, TNF-α, IL-12p40 and IL10. Results show average ± standard error of the mean. All results are representative of five mice per group and three independent experiments performed. Significant differences compared to no adjuvant controls are shown *p<0.5, **p<0.01 and ***p<0.001.

Protection induced by a single low dose immunization. To assess protection elicited by a single low-dose immunization in young mice, 2 week old A/J mice were immunized subcutaneously (s.c.), once with 10³ (AS) pRBC in CpG-ODN or control-ODN. Two weeks later, mice were challenged i.v. with 10⁵ homologous (AS) pRBC and (**A**) parasitemia or (**B**) disease severity monitored. Disease severity was assessed by performing clinical scores as described earlier. Data for individual mice are shown and are representative of three independent experiments performed.


Protection induced by low dose intramuscular immunization. To assess protection elicited by immunization using a more human-compatible route, A/J mice were immunized intramuscularly (i.m.) three times, three weeks apart, with 10³ (AS) pRBC in CpG-ODN or control-ODN. Two weeks later, mice were challenged i.v. with 10⁵ homologous (AS) pRBC and (A) parasitemia or (B) disease severity monitored. Disease severity was assessed by performing clinical scores as described earlier. Data for individual mice are shown and are representative of three independent experiments performed.


Supplementary Table 1


Disease severity assessment. Disease severity was assessed by performing clinical scores monitoring five parameters including: weight loss (0-2), posture (0-2), activity (0-2), fur texture (0-2) and percent parasitemia (0-2) for a maximal score of 10.




CYTOKINES AFTER CpG STIMULATION









CLINICAL PARAMETERS FOR DISEASE SEVERITY

Criteria	Grade 0	Grade 1	Grade 2
Weight loss	<10%	10-25%	>25%
Posture	Normal	Hunching no ted only at rest	Severe hunching impairs movement
Activity	Normal	Mild to moderately decreased	Stationary unless stimulated
Fur texture	Normal	Mild to moderate ruffling	Severe ruffling/poor grooming
Parasitemia	<5%	5-20%	>20%